Humacyte

HUMA

시가총액 US$1.19억

– Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end of the second quarter to 49 as of September 30, 2026. – Commercial momentum continues to build, driven by expanding hospital orders and surgeon interest.

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.36, signifying a -7.88% move from its prior day's close.

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.48, signifying a -4.26% move from its prior day's close.

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.5, signifying a -2.86% move from its prior day's close.

DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the addition of life science industry veterans Scott Coward and Paul Kuznik to the Company's Board of Directors, both of whom bring substantial experience in the areas of commercialization, enterprise leadership, and global operations.

The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.56, representing a -2% change from its previous close.

Humacyte, Inc. (HUMA) reached $0.59 at the closing of the latest trading day, reflecting a +2.23% change compared to its last close.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D.

– FDA authorizes extension of Symvess expiration dating from 18 months to 36 months – – Extended shelf life supported by additional stability data demonstrating Symvess continues to meet all established quality specifications throughout the 36-month dating period – DURHAM, N.C., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered human tissues, today announced that the U.S. Food and Drug Administration (FDA) has authorized an extension of the expiration dating period for Symvess® (acellular tissue engineered vessel-tyod, or ATEV) from 18 months to 36 months when stored refrigerated at 2°C to 8°C (36°F to 46°F).